ProQR Therapeutics shares are trading higher after Evercore ISI Group maintained its Outperform rating on the stock and raised its price target from $5 to $6.

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!